Dabrafenib (GSK2118436)

For research use only. Not for use in humans.

目录号：S2807 别名： GSK2118436A 中文名称：达拉菲尼

Dabrafenib (GSK2118436) Chemical Structure

CAS No. 1195765-45-7

Dabrafenib (GSK2118436, GSK2118436A)是一种突变型BRAFV600特异性抑制剂，无细胞试验中IC50为0.7 nM，作用于B-Raf(wt)和c-Raf效果分别低7和9倍。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1481.39	现货
5mg	RMB 733.64	现货
20mg	RMB 1394.46	现货
50mg	RMB 2235.84	现货
100mg	RMB 3261.37	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Dabrafenib (GSK2118436)发表文献178篇：

Nat Biotechnol, 2021, 10.1038/s41587-021-00837-3

PubMed: 33619394 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nature, 2019, 575(7781):203-209

PubMed: 31666698 ( click the link to review the publication )

Nat Med, 2018, 24(2):203-212

PubMed: 29334371 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Cancer Discov, 2018, 8(4):417-427

PubMed: 29431697 ( click the link to review the publication )

Nature, 2017, 550(7674):133-136

PubMed: 28953887 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2016, 352(6282):189-96

PubMed: 27124452 ( click the link to review the publication )

Nat Med, 2016, 22(9):1056-61

PubMed: 27500726 ( click the link to review the publication )

Cancer Cell, 2016, 12;30(3):485-498

PubMed: 27523909 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Nat Commun, 2021, 12(1):1747

PubMed: 33741929 ( click the link to review the publication )

Oncogene, 2021, 10.1038/s41388-020-01628-x

PubMed: 33500549 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):85

PubMed: 33446653 ( click the link to review the publication )

Oncol Rep, 2021, 45(4)14

PubMed: 33649790 ( click the link to review the publication )

J Physiol Biochem, 2021, 10.1007/s13105-021-00789-x

PubMed: 33587254 ( click the link to review the publication )

Mol Carcinog, 2021, 60(3):201-212

PubMed: 33595872 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202004707

PubMed: 32561648 ( click the link to review the publication )

EMBO Rep, 2020, e50163

PubMed: 33369872 ( click the link to review the publication )

Eur J Cancer, 2020, 144:17-30

PubMed: 33316635 ( click the link to review the publication )

Oncogene, 2020, 39(20):4132-4154

PubMed: 32238882 ( click the link to review the publication )
Cancers (Basel), 2020, 12(11)E3205

PubMed: 33143299 ( click the link to review the publication )

Cancers (Basel), 2020, 22;12(2) pii: E512

PubMed: 32098410 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2981

PubMed: 33066704 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2020, 10.1111/pcmr.12932

PubMed: 33000894 ( click the link to review the publication )

Cell Death Dis, 2020, 11(11):973

PubMed: 33184267 ( click the link to review the publication )

Cell Commun Signal, 2020, 18(1):156

PubMed: 32967672 ( click the link to review the publication )

ACS Infect Dis, 2020, acsinfecdis.0c00486

PubMed: 33183004 ( click the link to review the publication )

Sci Rep, 2020, 8;10(1):7826

PubMed: 32385388 ( click the link to review the publication )

Sci Rep, 2020, 27;10(1):5557

PubMed: 32221312 ( click the link to review the publication )

J Biol Chem, 2020, 295(8):2407-2420

PubMed: 31929109 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 13

PubMed: 32404982 ( click the link to review the publication )

Front Chem, 2020, 23;8:184

PubMed: 32266211 ( click the link to review the publication )

Pathol Oncol Res, 2020, 10.1007/s12253-020-00834-y

PubMed: 32591993 ( click the link to review the publication )

Anticancer Res, 2020, 40(4):1867-1874

PubMed: 32234874 ( click the link to review the publication )

Br J Cancer, 2020, 122(6):789-800

PubMed: 31932756 ( click the link to review the publication )

Biology (Basel), 2020, 9(8):E218

PubMed: 32785105 ( click the link to review the publication )

ESMO Open, 2020, 5(4):e000707

PubMed: 32817058 ( click the link to review the publication )

Neoplasia, 2020, 22(9):376-389

PubMed: 32629178 ( click the link to review the publication )

Vet Pathol, 2020, 300985820967449

PubMed: 33205710 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3946

PubMed: 32770055 ( click the link to review the publication )

Oncotarget, 2020, 11(44):3984-3997

PubMed: 33216827 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):387-402

PubMed: 32142667 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(49):31105-31113

PubMed: 33229534 ( click the link to review the publication )
Acta Neuropathol Commun, 2020, 8(1):139

PubMed: 32811569 ( click the link to review the publication )

Mol Cell, 2019, 76(6):872-884

PubMed: 31606273 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2197

PubMed: 31097693 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5143

PubMed: 31723142 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Cancer Res, 2019,

PubMed: 31362929 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0298-5

PubMed: 30742091 ( click the link to review the publication )

Eur J Cancer, 2019, 109:137-153

PubMed: 30721788 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):272

PubMed: 31227006 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):56

PubMed: 30728057 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31533235 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12824

PubMed: 31518489 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):128

PubMed: 31391125 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):119

PubMed: 31345255 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113616

PubMed: 31445021 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1225

PubMed: 30718660 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:223

PubMed: 31467489 ( click the link to review the publication )
Surgery, 2019, 10.1016/j.surg.2019.04.076

PubMed: 31585718 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Metabolites, 2019, 9(11)

PubMed: 31744229 ( click the link to review the publication )

Chembiochem, 2019, 10.1002/cbic.201900266

PubMed: 31152574 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0217399

PubMed: 31158244 ( click the link to review the publication )

Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520

PubMed: 31618797 ( click the link to review the publication )

Reprod Domest Anim, 2019, 54(5):741-749

PubMed: 30785650 ( click the link to review the publication )

Target Oncol, 2019, 14(5):619-626

PubMed: 31502118 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav8463

PubMed: 31453322 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

Ann Biomed Eng, 2019, 10.1007/s10439-019-02269-2

PubMed: 31020445 ( click the link to review the publication )

Sci Rep, 2019, 9(1):10865

PubMed: 31350469 ( click the link to review the publication )

Exp Gerontol, 2019, 126:110691

PubMed: 31421186 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31783660 ( click the link to review the publication )

Transl Oncol, 2019, 13(2):275-286

PubMed: 31874374 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Mol Cell, 2018, 69(6):923-937

PubMed: 29547721 ( click the link to review the publication )

Mol Cell, 2018, 70(5):920-935

PubMed: 29883609 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2500

PubMed: 29950559 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1466

PubMed: 29654229 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1090-1102

PubMed: 29196297 ( click the link to review the publication )
Clin Cancer Res, 2018, 24(14):3377-3385

PubMed: 29650750 ( click the link to review the publication )

Cancer research, 2018, 78(2):542-557

PubMed: 29180473 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):84-95

PubMed: 29133617 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Mol Oncol, 2018, 12(1):74-88

PubMed: 29112787 ( click the link to review the publication )

Neoplasia, 2018, 20(5):467-477

PubMed: 29605720 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(22):3974-3985

PubMed: 30137437 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9991

PubMed: 29968772 ( click the link to review the publication )

Front Pharmacol, 2018, 9:856

PubMed: 30154717 ( click the link to review the publication )

ACS Med Chem Lett, 2018, 9(12):1199-1204

PubMed: 30613326 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36503-36514

PubMed: 30559933 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):325

PubMed: 29487283 ( click the link to review the publication )

Oncotarget, 2018, 9(17):13324-13336

PubMed: 29568360 ( click the link to review the publication )

Small GTPases, 2018, 10.1080/21541248.2018.1446697

PubMed: 29634387 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10724

PubMed: 30013176 ( click the link to review the publication )

NPJ Syst Biol Appl, 2018, 4:39

PubMed: 30416750 ( click the link to review the publication )

Oncoimmunology, 2018, 8(1):e1512456

PubMed: 30546949 ( click the link to review the publication )

Cell Syst, 2018, 7(2):161-179

PubMed: 30007540 ( click the link to review the publication )
Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28294-28308

PubMed: 29983861 ( click the link to review the publication )

Neural Regen Res, 2018, 13(2):252-256

PubMed: 29557374 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4684-4696

PubMed: 28652244 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(19):3631-3645

PubMed: 28551825 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15523

PubMed: 29138474 ( click the link to review the publication )

Anal Bioanal Chem, 2017, 409(15):3749-3756

PubMed: 28429064 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2741-2751

PubMed: 29048639 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68208-68220

PubMed: 28978109 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(11 Pt B):2980-2992

PubMed: 28408301 ( click the link to review the publication )

Cell Death Differ, 2017, 24(1):83-97

PubMed: 27834956 ( click the link to review the publication )

Genome Res, 2017, 27(4):613-625

PubMed: 28179366 ( click the link to review the publication )

Oncogene, 2017, 36(27):3842-3851

PubMed: 28263969 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28350298 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(29):E5930-E5939

PubMed: 28684402 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(10)

PubMed: 29064427 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )
Blood Adv, 2017, 30;1(24):2147-2160

PubMed: 29296862 ( click the link to review the publication )

Nat Commun, 2016, 7:10274

PubMed: 26817517 ( click the link to review the publication )

Autophagy, 2016, 12(10):1776-1790

PubMed: 27464255 ( click the link to review the publication )

Leukemia, 2016, 30(4):937-46

PubMed: 26582644 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

J Biol Chem, 2016, 291(34):17804-15

PubMed: 27226552 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(7):778-84

PubMed: 26810603 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0152104

PubMed: 27015094 ( click the link to review the publication )

Oncotarget, 2016, 8(35):58021-58036

PubMed: 28938534 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30453-60

PubMed: 27028853 ( click the link to review the publication )

Sci Rep, 2016, 6:23713

PubMed: 27025703 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27557444 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75839-75853

PubMed: 27713119 ( click the link to review the publication )

Oncotarget, 2016, 7(12):15065-92

PubMed: 26918341 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.56

PubMed: 25952668 ( click the link to review the publication )

Mol Ther, 2015, 23(5):931-942

PubMed: 25619724 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(8):2021-2030

PubMed: 25748555 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Immunother, 2015, 38(1):12-23

PubMed: 25415284 ( click the link to review the publication )

Eur J Pharmacol, 2015, 762:283-92

PubMed: 26048310 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Cancer Res, 2015, 75(1):216-29

PubMed: 25381152 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(12):1934-7

PubMed: 26443648 ( click the link to review the publication )
Oncotarget, 2015, 6(38):40535-56

PubMed: 26497853 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(6):602-9

PubMed: 25795007 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )

J Clin Invest, 2014, 124(3):1406-17

PubMed: 24569374 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Transl Res, 2014, 164(5):411-23

PubMed: 25016932 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

产品安全说明书

Raf抑制剂选择性比较

生物活性

产品描述

Dabrafenib (GSK2118436, GSK2118436A)是一种突变型BRAFV600特异性抑制剂，无细胞试验中IC50为0.7 nM，作用于B-Raf(wt)和c-Raf效果分别低7和9倍。

靶点

B-Raf (V600E) ^[3] (Cell-free assay)	B-Raf ^[3] (Cell-free assay)	C-Raf ^[3] (Cell-free assay)
0.7 nM	5.2 nM	6.3 nM

体外研究

Dabrafenib对Raf激酶具有选择性，对B-Raf的活性比其它测试过的91%的激酶高400倍。 Dabrafenib抑制B-Raf^V600E激酶，导致ERK磷酸化降低和抑制细胞的增值，在特异性编码突变的B-Raf^V600E的癌细胞中细胞停滞在G1期。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
	NEfYWFdMcW6jc3WgRZN{[Xl?				MWPJcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiSHnzJJRi\2enZDDCMXJi\iCYNkCwSUBufXSjboSg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIHnud4VkfCClZXzsd{Bkdy2neIDy[ZN{cW6pIFPER\|M4KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJIJqd3SrbonsZZRm\C2PRVugdJJwfGWrbjDwbI9{eGixconsZZRqd25iYomgRYxxcGGVY4Ll[Y4h[XO\|YYmge4l1cCCLQ{WwJI9nKDBwMECwO{DPxE1?	NGHDbo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFY4Oyd-MkS5NFA3PzN:L3G+
SK-MEL-28	M3:4WGtqdmG\|ZTDBd5NigQ>?		M{Szc\|EhcA>?		MmezTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRiaX6gbJVu[W5iU1utUWVNNTJ6IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJGVTUyCyaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuNFA1KM7:TR?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyME[3N{c,OjR7MEC2O\|M9N2F-
HepG2	MWrLbY5ie2ViQYPzZZk>				MVvJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCHUlugdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjByNDFOwG0>	MkPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC2O\|MoRjJ2OUCwOlc{RC:jPh?=
COLO205	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9{MEWgZ4VtdCCycn;sbYZmemG2aX;uJJdqfGhiSVO1NEBw\iByLkCwO{DPxE1?	NVXXbo5bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA3PzNpPkK0PVAxPjd\|PD;hQi=>
HepG2	M2rtfGZ2dmO2aX;uJGF{e2G7		NWXWUIR[PDVibXnu	MWfEUXNQ	MXPJcohq[mm2aX;uJI9nKEGua{WgbY4hXEeILXLleIEue3SrbYXsZZRm\CCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBUdWGmMjDwbI9{eGixconsZZRqd25idILlZZRm\CCob4KgOFUhdWmwczDwdolweiC2bzDUS2Yu[mW2YTDzeIlufWyjdHnvckBu\WG\|dYLl[EBi\nSncjC2NEBucW6\|IHL5JI9lgXO\|ZYmgZoxwfCC\|Y3HucoVzKGGwYXz5d4l{KHerdHigTWM2OCCxZjCzMlch\|ryP	M3nNflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOlc{Lz5{NEmwNFY4OzxxYU6=
HFF	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlOwNVAh\|ryP	M4HtN\|czKGh?	M1LvPWROW09?	MYjJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhcHWvYX6gTGZHKGOnbHzzJIhiemKxcnnu[{B4cWymIIT5dIUhSi2UYX[ge4l1cCCLQ{WwJI9nKDNizszN	NITXfVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFY4Oyd-MkS5NFA3PzN:L3G+
SK-MEL-28	NGrXN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vHflExKM7:TR?=	NH;mOGc4OiCq	NUjlTlB[TE2VTx?=	NG\BNZNKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdD3kdol3\W5iU1utUWVNNTJ6IHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yNEOg{txO	NULEOpdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
A375P-F11	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PGe\|ExKM7:TR?=	Ml3RO\|IhcA>?	NGm4OW5FVVOR	Mmi2TY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRvZILpeoVvKEF\|N{XQMWYyOSClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvODdzIN88US=>	NYn3b3NFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
MALME-3M	MoT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PWelExKM7:TR?=	MkDtO\|IhcA>?	MoT4SG1UVw>?	NWC5T\|Q3UUN3ME2xJI5O	MojkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
UACC-62	NHnvOopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHTU4gyOCEQvF2=	NHfkfpQ4OiCq	NGnU[\|RFVVOR	MlnBTWM2OD1zIH7N	MmHmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
C32TG	MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUW5PWw2OTBizszN	MXu3NkBp	NHnBZ\|dFVVOR	NEDhZZhKSzVyPUGgcm0>	M{f3WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SK-MEL-1	MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;FVVExKM7:TR?=	M3m3UFczKGh?	Mmm1SG1UVw>?	MnrXTWM2OD1{IH7N	NIDBW4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
M14	MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUmxNEDPxE1?	NVXOSIFSPzJiaB?=	NInSSIhFVVOR	MoHNTWM2OD1{IH7N	M1;qfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SK-MEL-28	NEfXO5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DR[VExKM7:TR?=	NEX0N\|Y4OiCq	NYrZN45rTE2VTx?=	MV;JR\|UxRTNibl2=	MlPuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
A375	M3exXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nOR\|ExKM7:TR?=	NYTjcJZrPzJiaB?=	M1\ZcmROW09?	NGTJemdKSzVyPUSgcm0>	M4XJ[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
DU-4475	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGqyfnUyOCEQvF2=	NH3JVWE4OiCq	NHHTOXRFVVOR	NUDBcnloUUN3ME21JI5O	MofFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
UACC-257	NU\RSmJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzINVAh\|ryP	NFzyVHo4OiCq	MoHZSG1UVw>?	MoDWTWM2OD14IH7N	MmT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
Colo 205	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjiRVgyOCEQvF2=	NFHsSnQ4OiCq	MojsSG1UVw>?	M3n4SGlEPTB;NzDuUS=>	NHHlXHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SK-MEL-3	NEHNNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\PfYM2OTBizszN	NU\GR21SPzJiaB?=	MnjMSG1UVw>?	NVLBU5NpUUN3ME23JI5O	NEjmSnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SH-4	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jV[lExKM7:TR?=	MlPEO\|IhcA>?	MVTEUXNQ	MYDJR\|UxRThibl2=	M4TxS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
A101D	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHmPVEyOCEQvF2=	MUW3NkBp	MnzKSG1UVw>?	MkntTWM2OD17IH7N	NEfl[2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
ES-2	MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37Ye\|ExKM7:TR?=	MnrIO\|IhcA>?	M3HSXGROW09?	MlHpTWM2OD13MzDuUS=>	MmPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HT-29	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPr[3oyOCEQvF2=	M4SxTVczKGh?	NI[1fIJFVVOR	NXfT[JdRUUN3ME22OkBvVQ>?	M4PpRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW1417	NFHvS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrKZ5YyOCEQvF2=	MUK3NkBp	Mnz0SG1UVw>?	NUj0UHpnUUN3ME2xOVghdk1?	MnPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SW872	NYPoclRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3O4blExKM7:TR?=	M1u1[FczKGh?	NFPtWJNFVVOR	NFzURYxKSzVyPUO3O{BvVQ>?	M2XJfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
RKO	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHPVFUyOCEQvF2=	MlfvO\|IhcA>?	MlG0SG1UVw>?	M1faeGlEPTB;Mj61NlIh\|ryP	MlK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
A673	M3LSXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\GOGUyOCEQvF2=	M2\KeFczKGh?	MVzEUXNQ	NUTndIlkUUN3ME2xNEDPxE1?	NXLWUVFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
GCT	NETUb21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVKxNEDPxE1?	MX23NkBp	MWDEUXNQ	NHzPV5dKSzVyPUGwJO69VQ>?	NXjpfI9vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
WM-115	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWGxNEDPxE1?	NFjUVHE4OiCq	NWrUNJFxTE2VTx?=	MkfvTWM2OD13IH7N	M{XMRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
YUMAC	NXLhU\|lbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;vUlExKM7:TR?=	NWnIbYo4PzJiaB?=	NXTy[GdwTE2VTx?=	MUjJR\|UxRTVibl2=	MmnVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
OV-90	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY[xNEDPxE1?	MlLzO\|IhcA>?	NXjtc4xTTE2VTx?=	MW\JR\|UxRTJ7IH7N	NVTiPZZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H508	NXW4NI9kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUexNEDPxE1?	NWXWXFE4PzJiaB?=	NWHkNJRUTE2VTx?=	NWT3NIw1UUN3ME2xNEDPxE1?	NGr6NGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
MDA-MB-231	M2LLXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXGxNEDPxE1?	NGW5OG84OiCq	NXzjdlJ5TE2VTx?=	MWTJR\|UxRTFyIN88US=>	M1rXTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW756	NV;yeW1FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjrZ3gyOCEQvF2=	Ml;hO\|IhcA>?	M1u1dGROW09?	NG\5UWVKSzVyPUGwJO69VQ>?	M3nac\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW-837	NU[2cmlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrzNVAh\|ryP	NIDURmU4OiCq	MkHnSG1UVw>?	MXPJR\|UxRTFyIN88US=>	NFnnblU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
UMUC-3	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mne5NVAh\|ryP	MorQO\|IhcA>?	MWDEUXNQ	M4rRZmlEPTB;MUCg{txO	MmP2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
LS-174T	NIfYfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVmxNEDPxE1?	MXe3NkBp	M{PkWmROW09?	MVLJR\|UxRTFyIN88US=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
A549	MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXs[293OTBizszN	NU\0W5Z2PzJiaB?=	MUfEUXNQ	MUPJR\|UxRTFyIN88US=>	NV3rT5NPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SHP-77	NGTScWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnYNVAh\|ryP	Mnz2O\|IhcA>?	NXTzT5IxTE2VTx?=	MVvJR\|UxRTFyIN88US=>	M1X2[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW480	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTPdHkyOCEQvF2=	M{fIc\|czKGh?	NFPFR49FVVOR	MmLhTWM2OD1zMDFOwG0>	M3vSeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
DLD-1	MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUOxNEDPxE1?	NVPzfHhZPzJiaB?=	MWDEUXNQ	MX\JR\|UxRTFyIN88US=>	M33BdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
HCT-116	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXySHkyOCEQvF2=	MYS3NkBp	NGj6[IhFVVOR	MVnJR\|UxRTFyIN88US=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H747	M1TnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\MR\|ExKM7:TR?=	MUi3NkBp	NGPDdVBFVVOR	MlPiTWM2OD1zMDFOwG0>	M3HlTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
T-84	NH31e4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX6xNEDPxE1?	NUTUboxqPzJiaB?=	MWHEUXNQ	NHPKUlBKSzVyPUGwJO69VQ>?	NGCwU3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H460	M3nlVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XXeVExKM7:TR?=	NGPFc2Q4OiCq	NYXVO4ljTE2VTx?=	M2C0XGlEPTB;MUCg{txO	NXnienByRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
Calu-6	NX:4TXdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUP5b\|Z4OTBizszN	MYe3NkBp	M3vDT2ROW09?	NVTieoFxUUN3ME2xNEDPxE1?	NVHKTYRZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HCC-2998	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjPeml6OTBizszN	NXXwUpFpPzJiaB?=	NVKyPYdDTE2VTx?=	MoPwTWM2OD1zMDFOwG0>	MlPJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
LS1034	M4HORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInGUJIyOCEQvF2=	NYnWWXMyPzJiaB?=	M4TFdmROW09?	NUXNe4JxUUN3ME2xNEDPxE1?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
CHP-212	NH;HOo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHL0epEyOCEQvF2=	NEPnPJQ4OiCq	NHHUV4dFVVOR	MnXYTWM2OD1zMDFOwG0>	M2mwNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SK-N-AS	NUjYeHNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUSxNEDPxE1?	NYXyUGRrPzJiaB?=	MmXtSG1UVw>?	M2DVRmlEPTB;MUCg{txO	NF[wWpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
BFTC-905	NFf4cXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF22O4YyOCEQvF2=	NHnoZYw4OiCq	NGrhTnRFVVOR	NULLeYRyUUN3ME2xNEDPxE1?	NWHpcVA4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HuT78	NFHyXGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13HVlExKM7:TR?=	NVnRSJBxPzJiaB?=	M{LuRWROW09?	MYLJR\|UxRTV{IH7N	NXj6bGhsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
RPMI-8226	Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3ZNVAh\|ryP	NYP4bmh3PzJiaB?=	MVXEUXNQ	NGrET4dKSzVyPUK2N{BvVQ>?	NFrsWm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
BC-3	M4PMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTXNVAh\|ryP	NX3vb25KPzJiaB?=	NVvEfWpPTE2VTx?=	MlKzTWM2OD1{N{egcm0>	NGK2c4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
ACHN	M3vrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjNbGUyOCEQvF2=	M33TUFczKGh?	NF6w[VJFVVOR	NXrlc4JXUUN3ME2yPVQhdk1?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
JRT3-T35	M4LzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XiPVExKM7:TR?=	Mli5O\|IhcA>?	MV\EUXNQ	M17WdGlEPTB;Mkm1JI5O	MoX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SK-MES-1	M3PFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfvR40yOCEQvF2=	NFj0TWk4OiCq	MWTEUXNQ	NFXWe3hKSzVyPUOyPUBvVQ>?	NYjJXYR2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
CESS	MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M36zdFExKM7:TR?=	M1jDZ\|czKGh?	M17VN2ROW09?	NGHKfohKSzVyPUS5O{BvVQ>?	NUPWNlIyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
H4	MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnnRWlHOTBizszN	MWm3NkBp	M2XEc2ROW09?	NWWyU5lpUUN3ME22NVkhdk1?	NGnUNWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
BC-1	NXi1THF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXuxNEDPxE1?	M1:4[VczKGh?	MnHaSG1UVw>?	NVjGfXd5UUN3ME23NFQhdk1?	NGfHZZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
DB	NIfaVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWKxNEDPxE1?	NWHDWnBPPzJiaB?=	NYmyVGljTE2VTx?=	NV3NfWFQUUN3ME24O\|Mhdk1?	NGnFfnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
RPMI-6666	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjLV5MyOCEQvF2=	Mnf6O\|IhcA>?	M{PmXGROW09?	NGDQTWZKSzVyPUmyPEBvVQ>?	NFLUUpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
MC/CAR	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\GNVAh\|ryP	NGexdpA4OiCq	MXvEUXNQ	MXXJR\|UxRTFwMECyJO69VQ>?	NGLjbJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SNU-1	NGrvSG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nBelExKM7:TR?=	NW[4cY1IPzJiaB?=	NEfUcYlFVVOR	NVnDWpUzUUN3ME2xMlUxOSEQvF2=	M3fTVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
CEM/C1	Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVi1UYdFOTBizszN	M1LhZ\|czKGh?	NGn3TIZFVVOR	NHvGWlBKSzVyPUGuO\|c{KM7:TR?=	NXX3eFNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
GDM-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\xZlExKM7:TR?=	MUG3NkBp	MknSSG1UVw>?	M17MV2lEPTB;MT65PVch\|ryP	NEjBNI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
HT-1080	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfqfXYyOCEQvF2=	NEnVRos4OiCq	MVrEUXNQ	MlfRTWM2OD1{LkCwOEDPxE1?	NWPBNXNJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HL-60	NXrje2F4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPWc3p{OTBizszN	MlzHO\|IhcA>?	NVv4TWVOTE2VTx?=	NGPXc2NKSzVyPUKuNVc5KM7:TR?=	NXXGb2cxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
C3A	NVWwR5d4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfaR3kyOCEQvF2=	NV;iWXBYPzJiaB?=	NEPYcJhFVVOR	NX7aOZF4UUN3ME21MlQyPCEQvF2=	M1\yTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
MES-SA	MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXKxNEDPxE1?	NUPBOpBUPzJiaB?=	M{D5fWROW09?	MmrwTWM2OD14Lkm4PUDPxE1?	NVX2ToNNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
22Rv1	NXPhZ3pXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF:2OYgyOCEQvF2=	MoLmO\|IhcA>?	MoLWSG1UVw>?	NEjlTFNKSzVyPUGwJO69VQ>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
647-V	M3nMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nHSVExKM7:TR?=	M4nkSVczKGh?	MofvSG1UVw>?	MXjJR\|UxRTFyIN88US=>	MkPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
786-O	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LwclExKM7:TR?=	MVy3NkBp	MXHEUXNQ	M1zmfmlEPTB;MUCg{txO	M4T4Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
A172	NWLnV4t3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofUNVAh\|ryP	MWG3NkBp	MYLEUXNQ	Mn7xTWM2OD1zMDFOwG0>	M3LHb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
A204	Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVftc3FDOTBizszN	NXz6UYJmPzJiaB?=	MkezSG1UVw>?	MkLmTWM2OD1zMDFOwG0>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
A427	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXexNEDPxE1?	MlL3O\|IhcA>?	MVvEUXNQ	M3rwUmlEPTB;MUCg{txO	NHnZV4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
A431	NF;mclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHO2[I8yOCEQvF2=	NYDvS3dWPzJiaB?=	NGrXRpVFVVOR	M1\sOmlEPTB;MUCg{txO	NV;hZYFPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
A2780	Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVOxNEDPxE1?	MYK3NkBp	NHLMNodFVVOR	MnPMTWM2OD1zMDFOwG0>	MnTXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
ARH-77	Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVW4bFNvOTBizszN	M2LKclczKGh?	MmPBSG1UVw>?	MXvJR\|UxRTFyIN88US=>	M1mwclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
Be(2)C	MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\Qc5QyOCEQvF2=	MVG3NkBp	MkP3SG1UVw>?	Ml\1TWM2OD1zMDFOwG0>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
BT-20	M2jNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYq1OYt[OTBizszN	MWC3NkBp	NX7DeYxXTE2VTx?=	M3znNWlEPTB;MUCg{txO	MkHjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
BxPc3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nBdlExKM7:TR?=	NXjDSpFKPzJiaB?=	MYHEUXNQ	Mn;sTWM2OD1zMDFOwG0>	MnHoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
C-4 I	NX3OZ4JlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYexNEDPxE1?	MmfnO\|IhcA>?	MWTEUXNQ	MVPJR\|UxRTFyIN88US=>	Mk\vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
C33A	NGHpUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLFcFUyOCEQvF2=	MnOzO\|IhcA>?	MofaSG1UVw>?	M1HDSWlEPTB;MUCg{txO	MnjXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
CAL-27	M1\FNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnBe5BHOTBizszN	MlLlO\|IhcA>?	NFLuWHNFVVOR	MXzJR\|UxRTFyIN88US=>	NFq4XpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
CAL-62	M3zvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDuNVAh\|ryP	NWS0flVnPzJiaB?=	M3fCbGROW09?	NYDYO3pFUUN3ME2xNEDPxE1?	MoTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
Calu-3	NHzCdphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2r0UlExKM7:TR?=	MkHmO\|IhcA>?	Mn3jSG1UVw>?	MWXJR\|UxRTFyIN88US=>	M1vBUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
CaOV3	M{DOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDne2UyOCEQvF2=	M3LuWlczKGh?	NIW3V25FVVOR	NUXRXXNZUUN3ME2xNEDPxE1?	MlznQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
CGTHW1	NWnMVWhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTVRotROTBizszN	MorYO\|IhcA>?	MWLEUXNQ	M{Hh[mlEPTB;MUCg{txO	M2fGVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
CHL-1	MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorjNVAh\|ryP	NHfSNnM4OiCq	M4HmNGROW09?	NI\JUotKSzVyPUGwJO69VQ>?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
Colo320DM	NIK0b4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3HRZkyOCEQvF2=	MXe3NkBp	MkLTSG1UVw>?	NEXxc\|lKSzVyPUGwJO69VQ>?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
Colo704	NUXmOIs1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrpNVAh\|ryP	MkfhO\|IhcA>?	M2PXXWROW09?	M164R2lEPTB;MUCg{txO	NXrDNGUyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
COR-L23	M2Xvc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrQV5lxOTBizszN	NXzS[2w4PzJiaB?=	M4LKVWROW09?	MWDJR\|UxRTFyIN88US=>	Ml3OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
CRO-AP2	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnXepN3OTBizszN	MoDHO\|IhcA>?	M4jRdmROW09?	NIO4NpdKSzVyPUGwJO69VQ>?	MoTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
Daudi	MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYe1PJpGOTBizszN	M2XUZ\|czKGh?	NImzTJhFVVOR	NXuwXm5vUUN3ME2xNEDPxE1?	NYL6NG1PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
DOTC 24510	M{PkWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3uVJJnOTBizszN	Mo\kO\|IhcA>?	M2nQOWROW09?	NWLJRWFRUUN3ME2xNEDPxE1?	NXnmZlB[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
DU-145	Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV[xNEDPxE1?	NFzI[ZA4OiCq	Ml7JSG1UVw>?	MXHJR\|UxRTFyIN88US=>	NE\JT3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
EB-3	NInwN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXTNZIyOCEQvF2=	MVy3NkBp	NUPJWWw1TE2VTx?=	MmS1TWM2OD1zMDFOwG0>	Mmf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
EFM-19	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXUPZdUOTBizszN	MW[3NkBp	NVjhWHF5TE2VTx?=	NUO2bWM5UUN3ME2xNEDPxE1?	M1SwOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
EKVX	NV3jepZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnryNVAh\|ryP	MX:3NkBp	M4j5XmROW09?	MkLxTWM2OD1zMDFOwG0>	MmXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
FaDu	NY\wVplVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYGxNEDPxE1?	MUK3NkBp	M4r5VmROW09?	NV;sUIdFUUN3ME2xNEDPxE1?	M{jCdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
G401	M1nFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGL2fHkyOCEQvF2=	M1T2Z\|czKGh?	MkfkSG1UVw>?	NWf0N2x5UUN3ME2xNEDPxE1?	NYrvU\|h7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HCC-70	Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7pXJpqOTBizszN	M{\QblczKGh?	Mm\sSG1UVw>?	Mm\rTWM2OD1zMDFOwG0>	MmH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HCC-1954	NXm4flBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXiTYwyOCEQvF2=	MYK3NkBp	MVTEUXNQ	NWH3[HY5UUN3ME2xNEDPxE1?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
Hela	M4DObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHK3Xo8yOCEQvF2=	MlXQO\|IhcA>?	MoK4SG1UVw>?	M4TxUmlEPTB;MUCg{txO	MoS5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
Hep3B	MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnyU4Q5OTBizszN	MoX6O\|IhcA>?	MoL6SG1UVw>?	MWXJR\|UxRTFyIN88US=>	Ml7PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HMCB	NUHrXGVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPmNVAh\|ryP	NFTNfpM4OiCq	M4LFfGROW09?	M1m2RmlEPTB;MUCg{txO	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
HN5	Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV:5WY1GOTBizszN	M3\VelczKGh?	MnHQSG1UVw>?	MVLJR\|UxRTFyIN88US=>	M3r3XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
HOS	NX;1bWpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXYVI4yOCEQvF2=	NGTRfJM4OiCq	MWnEUXNQ	NFK1O45KSzVyPUGwJO69VQ>?	M3HTUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
HPAF-II	M3;PTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzpNVAh\|ryP	M2DHclczKGh?	MX7EUXNQ	NXj0UJNWUUN3ME2xNEDPxE1?	NU\seXJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
Hs746.T	NYWxTVRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jPT\|ExKM7:TR?=	MW[3NkBp	M1jHUWROW09?	NEX5WI9KSzVyPUGwJO69VQ>?	NVzS[3VRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HT	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXjNVAh\|ryP	MV:3NkBp	MoLKSG1UVw>?	MlnKTWM2OD1zMDFOwG0>	MmfsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HT-3	NIHLOZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEKzSVUyOCEQvF2=	MVW3NkBp	NHjGZoVFVVOR	NG\VcY9KSzVyPUGwJO69VQ>?	M2XwcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
HuNS-1	NWLj[VZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTQfpR3OTBizszN	Mmq1O\|IhcA>?	MVzEUXNQ	NWXS[HJiUUN3ME2xNEDPxE1?	NE\5Wpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
IGROV1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkC5NVAh\|ryP	NXP0R2RKPzJiaB?=	NYCzOo9uTE2VTx?=	MWfJR\|UxRTFyIN88US=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
J82	MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYWxNEDPxE1?	NXG1Sm11PzJiaB?=	NHzsXXpFVVOR	MljkTWM2OD1zMDFOwG0>	NFrmc4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
JM1	MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\yPYF[OTBizszN	MUS3NkBp	Mk\FSG1UVw>?	MXHJR\|UxRTFyIN88US=>	NHzxOFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Kato III	Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUixNEDPxE1?	MmH5O\|IhcA>?	M1\CRWROW09?	MknHTWM2OD1zMDFOwG0>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
KHOS-240S	NEn0eHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7uZVN4OTBizszN	MWq3NkBp	MXXEUXNQ	MV;JR\|UxRTFyIN88US=>	M3jqbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
KM-12	MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUexNEDPxE1?	NV7wW4pZPzJiaB?=	MWDEUXNQ	NF3FTHVKSzVyPUGwJO69VQ>?	Mne4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
KPL-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\KUGEyOCEQvF2=	Ml\IO\|IhcA>?	M2fuXWROW09?	MUHJR\|UxRTFyIN88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
KYSE-30	NHLrPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLPXG1MOTBizszN	NH;G[2E4OiCq	M1LHbWROW09?	NWTTUWY{UUN3ME2xNEDPxE1?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
LNCaP	M3S3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVyxNEDPxE1?	M2\sflczKGh?	NHLuXItFVVOR	MnjKTWM2OD1zMDFOwG0>	NGDw[oQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
MCF-7	NFj5Tm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;xNVAh\|ryP	NWq5SZI4PzJiaB?=	NYS3cYVDTE2VTx?=	MWjJR\|UxRTFyIN88US=>	NUDXNWZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
MC-IXC	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHjdHcyOCEQvF2=	NUnBZmRkPzJiaB?=	NFHpdY9FVVOR	NXHtNXoxUUN3ME2xNEDPxE1?	NVPlc2s3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
MDA-MB-175 VII	M2LUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrO[2gyOCEQvF2=	NXqw[XhkPzJiaB?=	MVnEUXNQ	NVfMSpZEUUN3ME2xNEDPxE1?	NHu1e2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
MDA-MB-468	NVTYZZZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{e5[FExKM7:TR?=	NF;nN2Q4OiCq	M2ni[mROW09?	M2HxNGlEPTB;MUCg{txO	MlmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
MiaPaCa	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHJNVAh\|ryP	MUW3NkBp	M17xWmROW09?	M4PsfWlEPTB;MUCg{txO	Mn\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
Molt-4	NWLxc4FYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2n3flExKM7:TR?=	M2\2RVczKGh?	NXHOc49FTE2VTx?=	MnPkTWM2OD1zMDFOwG0>	Mn3wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-ADR/RES	M3jEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XxeFExKM7:TR?=	Mlf5O\|IhcA>?	NULobY52TE2VTx?=	M4LLOGlEPTB;MUCg{txO	NWL1OlJYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H69	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknxNVAh\|ryP	M3fh[lczKGh?	Ml6zSG1UVw>?	NIDBT2lKSzVyPUGwJO69VQ>?	NF3SVGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H82	M3PQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfDdmcyOCEQvF2=	Mnn1O\|IhcA>?	NI\NPJNFVVOR	M33kR2lEPTB;MUCg{txO	NELkOow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-N87	NHS5fWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXKfooyOCEQvF2=	Ml\FO\|IhcA>?	NYX2flh4TE2VTx?=	M320TmlEPTB;MUCg{txO	M{jPSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H146	NIPmcJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nqOlExKM7:TR?=	MX:3NkBp	NX7QTIM4TE2VTx?=	MkLkTWM2OD1zMDFOwG0>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H157	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrRb4FDOTBizszN	M3\QO\|czKGh?	MWXEUXNQ	MVzJR\|UxRTFyIN88US=>	NIDoWZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H187	M3TFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvENVAh\|ryP	MX23NkBp	NY\xXYhoTE2VTx?=	NGruRoxKSzVyPUGwJO69VQ>?	M37BPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H209	Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXEXppROTBizszN	M33QTVczKGh?	M2TORmROW09?	NGOxVZVKSzVyPUGwJO69VQ>?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H226	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX2xNEDPxE1?	NE[wS3o4OiCq	M1LWZWROW09?	Ml\yTWM2OD1zMDFOwG0>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H292	NVn5UY95T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4O0SVExKM7:TR?=	M2jGVlczKGh?	MnPPSG1UVw>?	MX3JR\|UxRTFyIN88US=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H322	MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULQOZJuOTBizszN	NHHU[Wo4OiCq	Mkf2SG1UVw>?	MkXnTWM2OD1zMDFOwG0>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H358	M1XVVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWCxNEDPxE1?	MVu3NkBp	M3\ZeWROW09?	NXnCVHREUUN3ME2xNEDPxE1?	M{TL[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H520	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUKxNEDPxE1?	MWK3NkBp	MVjEUXNQ	M2ru[mlEPTB;MUCg{txO	M2fwPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H526	M4fmZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELYR2MyOCEQvF2=	MoLzO\|IhcA>?	M{nDWGROW09?	NXq4WnBbUUN3ME2xNEDPxE1?	NX3BUFZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H630	NX7EbYxbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrOZVhpOTBizszN	MnrNO\|IhcA>?	NUjuTGl5TE2VTx?=	NE\hbVlKSzVyPUGwJO69VQ>?	NXT1emJ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H661	NFPmfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\IcW8yOCEQvF2=	MWO3NkBp	MXfEUXNQ	M4DPdWlEPTB;MUCg{txO	M{KxZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H716	MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;DNVAh\|ryP	M2HqS\|czKGh?	M{jOWGROW09?	M{XXfGlEPTB;MUCg{txO	M2nsT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H1563	NYP2WmpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\TdXVJOTBizszN	Mn;BO\|IhcA>?	MUjEUXNQ	M2PaWmlEPTB;MUCg{txO	NFXyUFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H1792	NGjwSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjxXVJSOTBizszN	NF\QOHI4OiCq	M4TsZ2ROW09?	NI\BRXdKSzVyPUGwJO69VQ>?	NWHyOIVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H2030	Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1n2SFExKM7:TR?=	MUS3NkBp	M1r6Z2ROW09?	MortTWM2OD1zMDFOwG0>	NInaOJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H2052	MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWe2[\|VSOTBizszN	MXu3NkBp	NFrCcGJFVVOR	NUK3O\|kxUUN3ME2xNEDPxE1?	NGnMPGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H2122	NXXIe2hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;0e\|ExKM7:TR?=	NWDFflhzPzJiaB?=	MoLpSG1UVw>?	MmXaTWM2OD1zMDFOwG0>	NWLSPFNlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H2228	Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnoe4kyOCEQvF2=	NYfWbolVPzJiaB?=	M2rjRWROW09?	NF\k[mdKSzVyPUGwJO69VQ>?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
OE-19	MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvxd2ZpOTBizszN	MYm3NkBp	NUTMcVNITE2VTx?=	NYfGXZFlUUN3ME2xNEDPxE1?	M2fUWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
OE-21	Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17BTFExKM7:TR?=	MkTMO\|IhcA>?	MVjEUXNQ	MnTUTWM2OD1zMDFOwG0>	MnHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
OE-33	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVGxNEDPxE1?	MYW3NkBp	NXm2WVFPTE2VTx?=	MnrMTWM2OD1zMDFOwG0>	M1TwVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
OVCAR-3	MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvyNVAh\|ryP	M{XHeVczKGh?	NHixclRFVVOR	MmnhTWM2OD1zMDFOwG0>	NIrVTJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
OVCAR-4	NH[2XZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nId\|ExKM7:TR?=	NGTkXpM4OiCq	MUjEUXNQ	MXzJR\|UxRTFyIN88US=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
OVCAR-5	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUOxNEDPxE1?	MWC3NkBp	M3LUSWROW09?	MUHJR\|UxRTFyIN88US=>	M{XSZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
P3HR-1	Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fL[FExKM7:TR?=	NVXRWVlwPzJiaB?=	MknySG1UVw>?	M17je2lEPTB;MUCg{txO	NUnlTWRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
PC-3	NEewbG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUCxNEDPxE1?	NE\UNpg4OiCq	MVLEUXNQ	NGjsbXlKSzVyPUGwJO69VQ>?	NGrVSmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Raji	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M133dVExKM7:TR?=	NHP0e4o4OiCq	M1HQPWROW09?	MYHJR\|UxRTFyIN88US=>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
RD	M4fJZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWSxNEDPxE1?	MmTrO\|IhcA>?	MXTEUXNQ	M2\IRWlEPTB;MUCg{txO	NYXKNJh5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
RD-ES	M2XNPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XNcFExKM7:TR?=	M17z[lczKGh?	MoDCSG1UVw>?	MnHrTWM2OD1zMDFOwG0>	MmnIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
RL	NWC1UI1NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\jNVAh\|ryP	M1HsW\|czKGh?	MoPUSG1UVw>?	NUT1fVF1UUN3ME2xNEDPxE1?	MmPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SaOS2	NWTKUVZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fT[VExKM7:TR?=	M{Tkb\|czKGh?	NHvxcWlFVVOR	MUHJR\|UxRTFyIN88US=>	NVP2TnNSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SCC-9	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXexNEDPxE1?	NHvPN2Q4OiCq	M2PyOGROW09?	NFvNZo5KSzVyPUGwJO69VQ>?	M2fGeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SCC-12	NEj3dIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13OS\|ExKM7:TR?=	MVq3NkBp	M2izNmROW09?	MnzDTWM2OD1zMDFOwG0>	M3e3T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SCC-13	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvieIwyOCEQvF2=	NVLDTI4xPzJiaB?=	MXXEUXNQ	MYLJR\|UxRTFyIN88US=>	M4HJVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SCC-15	MlXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\rNVAh\|ryP	MmPvO\|IhcA>?	NX;5dW1iTE2VTx?=	NXjiXZl{UUN3ME2xNEDPxE1?	NFTOb5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SCC-25	MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLZNVAh\|ryP	MV:3NkBp	MkO5SG1UVw>?	NV7pSnBRUUN3ME2xNEDPxE1?	Ml3JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SCLC-3	NXLIN2ozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfsdlUyOCEQvF2=	Mkn4O\|IhcA>?	MlzLSG1UVw>?	NIXlbJFKSzVyPUGwJO69VQ>?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SF-268	NGjOZm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnvOFdWOTBizszN	MmSwO\|IhcA>?	M2nCUWROW09?	NV3CNFZVUUN3ME2xNEDPxE1?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SF-295	M1PzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;jelExKM7:TR?=	NH\INHA4OiCq	M3Tn[GROW09?	MWDJR\|UxRTFyIN88US=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SJRH30	NXHXU4dZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XvblExKM7:TR?=	NGTifo04OiCq	NH32XmdFVVOR	Ml;oTWM2OD1zMDFOwG0>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SK-BR-3	Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7DNXYyOCEQvF2=	NHT6Z4o4OiCq	MYHEUXNQ	MnOxTWM2OD1zMDFOwG0>	NWq1bJIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SK-LMS-1	MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX6xNEDPxE1?	MoPtO\|IhcA>?	NUe1bJdxTE2VTx?=	NX3zS3hGUUN3ME2xNEDPxE1?	NETOZZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SK-N-DZ	M{Dl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYqxNEDPxE1?	NFLaNXM4OiCq	NXLTTZRuTE2VTx?=	NIfBXodKSzVyPUGwJO69VQ>?	M{Kw[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SK-N-F1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXxPWVCOTBizszN	MXO3NkBp	NHnPcmlFVVOR	MULJR\|UxRTFyIN88US=>	NFvpcGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SKOV-3	MoG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDqOIIyOCEQvF2=	M13We\|czKGh?	MWDEUXNQ	NVHKPYhKUUN3ME2xNEDPxE1?	MorHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SK-UT-1	M2rP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfGNVAh\|ryP	MVG3NkBp	Mkj3SG1UVw>?	Ml65TWM2OD1zMDFOwG0>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SN12C	NVv2OHV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn61NVAh\|ryP	Mk\WO\|IhcA>?	NWHzW49mTE2VTx?=	M1;Sc2lEPTB;MUCg{txO	MnrLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SNB-19	NUK0c2hGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV6xNEDPxE1?	MoPkO\|IhcA>?	MVnEUXNQ	NH7Nd2FKSzVyPUGwJO69VQ>?	NXzXZXBMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SNU-5	M1\y[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvLfpAyOCEQvF2=	M4DmVlczKGh?	M2LFfmROW09?	MXPJR\|UxRTFyIN88US=>	NGjrco89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SNU-16	M1nuRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXqxNEDPxE1?	MW[3NkBp	NVr4R2xTTE2VTx?=	M{T2TmlEPTB;MUCg{txO	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SNU-398	MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVKxNEDPxE1?	NFzVRoQ4OiCq	M322[2ROW09?	MnPJTWM2OD1zMDFOwG0>	M3;lflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SNU-449	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjhZY4yOCEQvF2=	M2jnWlczKGh?	MVPEUXNQ	MoPYTWM2OD1zMDFOwG0>	NUDRboxrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SR	M3LRTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDJRZEyOCEQvF2=	M3HIcVczKGh?	NI\5ZmhFVVOR	MoDuTWM2OD1zMDFOwG0>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
ST486	NIrSe3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfQOo4yOCEQvF2=	MkPXO\|IhcA>?	NGLqemdFVVOR	NHzzdGNKSzVyPUGwJO69VQ>?	M2jTTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW579	NIPaTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;mNVAh\|ryP	MY[3NkBp	NYjOcJU6TE2VTx?=	MlrOTWM2OD1zMDFOwG0>	NV3kWHJKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SW684	NHzEc5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\hZm9pOTBizszN	M4X2OFczKGh?	MoOySG1UVw>?	Mm\2TWM2OD1zMDFOwG0>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SW-780	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjBeZQyOCEQvF2=	M3PBOFczKGh?	Mnv0SG1UVw>?	NYW5cFhRUUN3ME2xNEDPxE1?	NWDrfnlURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SW900	M3nGb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\NNVAh\|ryP	MX[3NkBp	MUDEUXNQ	M17Cc2lEPTB;MUCg{txO	NH;GTXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SW1088	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHL[XJ7OTBizszN	NGL5b4Y4OiCq	M1LlZmROW09?	MX7JR\|UxRTFyIN88US=>	NXHtZpFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SW1463	M2H6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rlZVExKM7:TR?=	Mli2O\|IhcA>?	NGTnUI9FVVOR	MXTJR\|UxRTFyIN88US=>	NILtVVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SW1990	NWnDWZFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYWxNEDPxE1?	M1P0[FczKGh?	NITMSHJFVVOR	MkTOTWM2OD1zMDFOwG0>	M2LGVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
T47D	MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnUNVAh\|ryP	M1HvXlczKGh?	M4rQXGROW09?	NXXYb\|VPUUN3ME2xNEDPxE1?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
TE381.T	NVHZSo1NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVmxNEDPxE1?	Mn\iO\|IhcA>?	MXPEUXNQ	M2HNNWlEPTB;MUCg{txO	MnrWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
TK-10	NEjyd21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV6xNEDPxE1?	NULxUWRVPzJiaB?=	M2fWUmROW09?	NXLqZo5IUUN3ME2xNEDPxE1?	M3\DV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
U2OS	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTUNVAh\|ryP	NYHXcnJyPzJiaB?=	NF:2XGtFVVOR	M2[4VGlEPTB;MUCg{txO	M4Tq[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
U251	NXG2Ulc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfHNVAh\|ryP	M1vWeVczKGh?	NEPOVFFFVVOR	NFzk[ldKSzVyPUGwJO69VQ>?	MnPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
UACC-812	NHXiR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWexNEDPxE1?	NIjTdVE4OiCq	MWDEUXNQ	MYDJR\|UxRTFyIN88US=>	M37QOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
YAPC	NYXVcGRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\yNVAh\|ryP	MWO3NkBp	MnqySG1UVw>?	NXTH[JhZUUN3ME2xNEDPxE1?	MlX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
ZR-75-1	Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYniRpp6OTBizszN	MUm3NkBp	NXHNPWRJTE2VTx?=	MV3JR\|UxRTFyIN88US=>	NWnacJJCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
A375	MYPGeY5kfGmxbjDhd5NigQ>?	MUCxMlIh\|ryP	MVm0JIg>	MnvlSG1UVw>?	MoDJTY5pcWKrdHnvckBw\iCyaH;zdIhwenmuYYTpc44hd2ZiTVXLMEBGWktuIHHu[EBUPlB?	M4OzbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{i5OFcyLz5{MkO4PVQ4OTxxYU6=
YUSIT1	MVfGeY5kfGmxbjDhd5NigQ>?			MonGSG1UVw>?	NVTaelltemWmdXPl[EB{\W6\|aYTpeol1gSC5aYToJGlEPTBiPjCwMlUh\|ryP	NILoZlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO4PVQ4OSd-MkKzPFk1PzF:L3G+
MeWo	M17tVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NIe2PVZFVVOR	NEHPWJNKSzVyIE2gPVg4KG6P	M3q1T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEG4OVI1Lz5{NkCxPFUzPDxxYU6=
WiDr	MoHpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			Mmj1SG1UVw>?	NY\TZ4xiUUN3MDC9JFc3KG6P	NGLENJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCxPFUzPCd-Mk[wNVg2OjR:L3G+
Colo-205	M1TPRWZ2dmO2aX;uJIF{e2G7	M{i5XlEh\|ryP	NVuyfJBUPCCm	M1\xRmROW09?	MmPoTY5lfWOnZDDhJIhq\2iueTDjc41x[XKjYnzlJINwdXCjY4Tpc44heGinbn;0fZBm	M1;DPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{ixNVUzLz5{NUO4NVE2OjxxYU6=
RBW-1	M3LIPGZ2dmO2aX;uJIF{e2G7	Ml3oNUDPxE1?		MljtSG1UVw>?	M1K4TG5wKHKnZIXjeIlwdiCxZjDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>?	NGfkO\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OVY6OCd-MkS4PFU3QTB:L3G+
RBO-1	MYTGeY5kfGmxbjDhd5NigQ>?	MlLVNUDPxE1?		M4fyTGROW09?	MkDrTY5pcWKrdHnvckBw\iCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=>	MnP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OEW2PVAoRjJ2OEi1OlkxRC:jPh?=
RBO-2	NYrHOmhQTnWwY4Tpc44h[XO\|YYm=	NVzT[lE1OSEQvF2=		NGDtVXRFVVOR	NFzaUIFKdmirYnn0bY9vKG:oIDDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>?	NFf3boo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OVY6OCd-MkS4PFU3QTB:L3G+
RBOW	NVf1TYdETnWwY4Tpc44h[XO\|YYm=	M4iwVVEh\|ryP		M{[zNmROW09?	NFPMU2ZKdmirYnn0bY9vKG:oIDDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>?	M1j2eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEi1OlkxLz5{NEi4OVY6ODxxYU6=
M257	NXXwZYtqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jOUlExOCCwTR?=	NGnVflM4OiCq		MnjUSI9meyCwb4SgbY5pcWKrdDDwdo9tcW[ncnH0bY9vKG:oIF2yOVch[2WubDDoZZJjd3W{aX7nJJdqdGRidInw[UBDWkGI	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzN{S0Okc,OjN\|MUe0OFY9N2F-
LCP	M2[4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXGxNFAhdk1?	M2HvflczKGh?		NYn2Z3hCUW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKG:oIFzDVEBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCwVkBufXSjboTheIlwdg>?	NISzc289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxO\|Q1Pid-MkOzNVc1PDZ:L3G+
WM266	Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYqxNFAhdk1?	NEXrTYQ4OiCq		MVPJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhX01{Nk[gZ4VtdCCqYYLic5VzcW6pIFLSRWYhXjZyMVSgcZV1[W62YYTpc44>	M1W2dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{G3OFQ3Lz5{M{OxO\|Q1PjxxYU6=
M257	MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\DNVAxKG6P	NEHucZI4OiCq		M{jJNGRw\XNibn;0JIlvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDNNlU4KGOnbHygbIFz[m:3cnnu[{B4cWymIIT5dIUhSlKDRh?=	Moe5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUe0OFYoRjJ\|M{G3OFQ3RC:jPh?=
LCP	MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zsVlExOCCwTR?=	NUX5NmVnPzJiaB?=		M3PvSWlvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDMR3Ah[2WubDDoZZJjd3W{aX7nJGJTSUZiVk[wNHIhdXW2YX70ZZRqd25?	NE\hPXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxO\|Q1Pid-MkOzNVc1PDZ:L3G+
WM266	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXZNVAxKG6P	NE[1UVE4OiCq		M1G5VWlvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDXUVI3PiClZXzsJIhiemKxdYLpcochSlKDRjDWOlAxTCCvdYThcpRifGmxbh?=	MnHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUe0OFYoRjJ\|M{G3OFQ3RC:jPh?=
A375	MX\CVmFHKGOxbYDleIl1cX[nIHLpcoRqdmdiYYPzZZk>		NYTKUI9UOTVibXnu		M4r0WWlEPTBiPTCwMlAxPiEQvF2=	MlHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkW4NFQoRjJ3OU[1PFA1RC:jPh?=
A375	MmjBSpVv[3Srb36gZZN{[Xl?		MWq3NkBp		MV7JR\|UxKD1iMD6wNVEh\|ryP	NHjPUXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2OVgxPCd-MkW5OlU5ODR:L3G+
A375	MnPXRXJCTiClb33w[ZRqfGm4ZTDibY5lcW6pIHHzd4F6		NHz2bJgyPSCvaX6=		NFnCT3NKSzVyIE2gNE4xOjZizszN	NU\TdYp5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlU5ODRpPkK1PVY2QDB2PD;hQi=>
A375	MkXOR3JCTiClb33w[ZRqfGm4ZTDibY5lcW6pIHHzd4F6		Mm[wNVUhdWmw		Ml;vTWM2OCB;IECuNVUh\|ryP	MojlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkW4NFQoRjJ3OU[1PFA1RC:jPh?=
HCT116	NFK1VpFHfW6ldHnvckBie3OjeR?=				M3LjUmlEPTBiPTC1Mlg5KM7:TR?=	NUPMOpZIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlU5ODRpPkK1PVY2QDB2PD;hQi=>
A375	NYLNO2RUTnWwY4Tpc44h[XO\|YYm=		M1nYblEhcA>?		MVHJR\|UxKD1iMD6wNFEh\|ryP	M2HHWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEi1OlczLz5{N{C4OVY4OjxxYU6=
MIAPaCa2	M3PFdGZ2dmO2aX;uJIF{e2G7		NHvPUXoyKGh?		NUHtTJNUTUN3MDC9JFAvPTJ7IN88US=>	NVG2[odXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewPFU3PzJpPkK3NFg2Pjd{PD;hQi=>
A375	MU\GeY5kfGmxbjDhd5NigQ>?				M3vSZ2lEPTBiPTCwMlAxPCEQvF2=	M4HMb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[xPFI4Lz5{OUS2NVgzPzxxYU6=
SK-MEL-28	NFPSV4pEgXSxdH;4bYNqfHliYYPzZZk>		MoHPO\|IhcA>?		NXPwZ\|F[UUN3MDC9JFAvODR\|IN88US=>	M3T5UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[xPFI4Lz5{OUS2NVgzPzxxYU6=
Sf9	M{n4eWZ2dmO2aX;uJIF{e2G7		MXu2NEBucW5?		MWrJR\|UxKD1iMD6wNFkh\|ryP	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5NEGzO{c,Ojd5N{SxN\|c9N2F-
SK-MEL-28	NEXBcmVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3f4UlQ5KGh?		MV7Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTT{1OTUxvMkigZ4VtdHNiaHHyZo9zcW6pIFLSRWYhXjZyMFWgcZV1[W62IH3lZZN2emWmIHHmeIVzKDR6IHjyd{Bz\XOjeoXybY4h[XO\|YYm=	M3O1S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVM4Lz5{N{e3OFE{PzxxYU6=
SK-MEL-28	NULoVWJUT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWXGb3BPPDhiaB?=		NInhNJRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytNlgh[2WubIOgbIFz[m:{aX7nJGJTSUZiVk[wNGUhdXW2YX70JJBz\WmwY4XiZZRm\CCob4KgNUBpeiCob3zsc5dm\CCkeTDpdpJi\GmjdHnvckBw\iBzLkGzJItYN21{IGXWMYxq\2i2IH\vdkA2KG2rboOgcYVie3W{ZXSgZYZ1\XJiNEigbJJ{KHKnc3H6eZJqdiCjc4PhfS=>	NX7hXFh5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O\|QyOzdpPkK3O\|c1OTN5PD;hQi=>
SK-MEL-28	Mo[5R5l1d3SxeHnjbZR6KGG\|c3H5		MXS0PEBp		M1LaUmN6fG:\|dHH0bYMh[WO2aY\peJkhcW5iaIXtZY4hW0tvTVXMMVI5KGOnbHzzJIhiemKxcnnu[{BDWkGIIG[2NFBGKG23dHHueEBifCBzIHHu[EA{OCC3TTDt[YF{fXKnZDDh[pRmeiB2ODDodpMhemW\|YYr1dolvKGG\|c3H5	NVjxWVRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O\|QyOzdpPkK3O\|c1OTN5PD;hQi=>
DAOY	NWDMXGhwWHKrbXHyfUB{[3KnZX6gZZN{[Xl?				MlTGdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	NFO4W\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	M3\MXnBzcW2jcomgd4Nz\WWwIHHzd4F6				MXnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	M1;6N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	M3vre3BzcW2jcomgd4Nz\WWwIHHzd4F6				M37LZZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	NIfsfoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pMEK / pERK / ERK; PubMed: 31158244 PLoS One Cell lines as shown were treated with dabrafenib, over a dose range, for 1 hour. UT = untransfected. Expression and/or phosphorylation of the indicated proteins were assessed by immunoblot. p-S6 / p-AKT308 / p-AKT473; PubMed: 24735930 Mol Cancer Western blot analysis of phosphorylated proteins in MAPK and the PI3K-AKT pathway after 24 hours exposure to increasing concentrations of dabrafenib. β-catenin; PubMed: 29167314 Mol Cancer Ther HT-29 cells were treated with BRAF inhibitors Dabrafenib (2 μM), GDC-0879 (4 μM) or Vemurafenib (2 μM) for indicated times. The whole cell lysates were used for western blot with indicated antibodies.	31158244 24735930 29167314
Growth inhibition assay	IC50; PubMed: 24735930 Mol Cancer A panel of 23 BRAF(V600) mutant human melanoma cell lines was treated with serial dilutions (1-10,000 nM) of dabrafenib (A) for 72-120 hours to assess cell viability. The bars represent the average IC50 value of two or more independent experiments in duplicates and the error bars represent the SEM.	24735930

体内研究

Dabrafenib（口服）抑制B-RafV600E突变的黑色素瘤（A375P）的生长，在免疫受损小鼠中皮下注射结肠癌（Colo205），Dabrafenib（口服）同样能抑制肿瘤生长。 ^[1]

参考文献

溶解度 (25°C)

体外	DMSO	30 mg/mL (57.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+45% PEG 300+2% Tween 80+ddH2O	5 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Dabrafenib (GSK2118436) SDF

分子量	519.56
化学式	C₂₃H₂₀F₃N₅O₂S₂
CAS号	1195765-45-7
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	GSK2118436A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04547946	Not yet recruiting	Drug: dabrafenib + trametinib	Malignant Melanoma	Novartis Pharmaceuticals\|Novartis	January 29 2021	--
NCT04666272	Not yet recruiting	Drug: dabrafenib\|Drug: trametinib	Melanoma	Novartis Pharmaceuticals\|Novartis	December 22 2020	--
NCT04452877	Recruiting	Drug: Dabrafenib\|Drug: Trametinib	Carcinoma Non-Small-Cell Lung	Novartis Pharmaceuticals\|Novartis	August 19 2020	Phase 2
NCT04059224	Recruiting	Drug: Trametinib\|Drug: Dabrafenib	Stage IV Melanoma\|Stage III Melanoma	Universitair Ziekenhuis Brussel	January 28 2019	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

泛Raf抑制剂

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA批准的Raf抑制剂

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
最新的Raf抑制剂

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

研究领域

产品类型

定制您的化合物库

Dabrafenib (GSK2118436)

客户使用Selleck生产的Dabrafenib (GSK2118436)发表文献178篇：

产品安全说明书

Raf抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Dabrafenib (GSK2118436) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-01-06)

技术支持

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

相关Raf产品